A stapled peptide inhibitor of MDM2 enables pharmacological activation of p53 in zebrafish

This study demonstrates that the stapled peptide sulanemadlin specifically activates p53 in zebrafish by overcoming species-specific binding barriers that limit small-molecule inhibitors, thereby enabling the first pharmacological assessment of p53 regulation in vivo without inducing apoptosis.

The Gist

The Big Picture: A Broken Security System

Imagine your body is a bustling city. Inside every cell, there is a Security Chief named p53. His job is to patrol the streets, check for damage, and if things look dangerous (like a cancerous mutation), he sounds the alarm to either fix the problem or shut down the cell to prevent a disaster.

However, the Security Chief has a nemesis: a bodyguard named MDM2. MDM2's job is to keep p53 calm and inactive. In fact, MDM2 is so good at his job that he often drags p53 away to the "trash can" (degradation) before p53 can do his work. In cancer, MDM2 is often overactive, leaving the city defenseless.

Scientists want to stop MDM2 so p53 can wake up and save the day. They have developed "handcuffs" (drugs) to stop MDM2 from grabbing p53.

The Problem: The Wrong Key for the Lock

The researchers in this paper were trying to test these handcuffs in zebrafish. Zebrafish are like tiny, transparent test tubes for humans; they are great for studying diseases because their biology is very similar to ours.

However, they hit a snag. The "handcuffs" (small molecule drugs like nutlin-3a and navtemadlin) that work perfectly on human MDM2 were failing in zebrafish.

The Analogy:
Imagine MDM2 is a high-tech lock.

• In Humans, the lock has a specific pin (a Histidine amino acid) that fits perfectly with the key (the drug).
• In Zebrafish, evolution changed that pin to a different shape (a Proline amino acid).
• The human keys are too big or the wrong shape to fit the zebrafish lock. They just slide right off.

Because the drugs couldn't stick to the zebrafish MDM2, they couldn't free the p53 Security Chief. Previous methods to wake up p53 in fish involved blasting them with radiation or using drugs that had messy side effects (like causing the fish to die or get sick in other ways), making it hard to study p53 specifically.

The Solution: The "Stapled" Super-Tool

The researchers tested a new type of tool: a stapled peptide called Sulanemadlin.

The Analogy:
If the small molecule drugs were like a single key, the stapled peptide is like a giant, flexible grappling hook.

• Instead of trying to fit into one tiny hole, this hook wraps around a large part of the lock.
• It has a "staple" (a chemical bridge) that holds it in a rigid, strong shape, allowing it to hug the zebrafish MDM2 tightly, regardless of that one changed pin.

The Results:

1. It Stuck: The stapled peptide grabbed onto the zebrafish MDM2 with incredible strength, just as well as it does in humans.
2. It Woke Up the Chief: Once MDM2 was handcuffed, the p53 Security Chief woke up and started shouting orders. The fish started producing genes that stop cell division (cell cycle arrest).
3. No Collateral Damage: This is the best part. Usually, waking up p53 is like pulling the fire alarm: it causes panic and destruction (apoptosis/cell death). But this stapled peptide woke p53 up just enough to stop the cells from growing, without causing a mass panic or killing the cells.

Why This Matters

Think of this like finding a surgical scalpel when you previously only had a sledgehammer.

• Old Way: To study p53 in fish, scientists had to use radiation or drugs that caused the fish to die or suffer from other issues. It was like trying to study how a car engine works by smashing the car with a hammer.
• New Way: With Sulanemadlin, scientists can now gently "tap" the p53 system in zebrafish to see how it regulates aging, diabetes, or cancer, without accidentally killing the fish or causing chaos.

Summary

The paper shows that while standard drugs fail to work on zebrafish because of a tiny genetic difference, a special "stapled" drug can bypass this problem. It acts like a universal adapter, allowing scientists to finally study the p53 tumor suppressor in zebrafish with precision, opening the door to better understanding and treating diseases like cancer and aging.

Technical Summary

1. Problem Statement

The tumor suppressor protein p53 is a critical regulator of cellular stress responses, including cell cycle arrest, senescence, and apoptosis. Studying p53 dysregulation in diseases like cancer, aging, and diabetes requires precise in vivo models. Zebrafish (Danio rerio) are a premier vertebrate model due to the evolutionary conservation of p53 structure and function.

However, a significant methodological gap exists:

• Current Limitations: Existing methods to activate p53 in zebrafish rely on inducing DNA damage (e.g., high-dose radiation) or using non-specific kinase inhibitors (e.g., roscovitine). These approaches trigger broad stress responses and widespread apoptosis, making it difficult to isolate p53-specific transcriptional programs from general cellular damage.
• The Species Barrier: While small-molecule MDM2 inhibitors (which block p53 degradation) are effective in humans and mice, their efficacy in zebrafish has been poor. The authors hypothesized that specific amino acid variations in the zebrafish Mdm2 binding pocket reduce the binding affinity of these small molecules, preventing effective p53 activation.

2. Methodology

The study employed a multi-disciplinary approach combining biophysics, computational biology, and in vivo zebrafish assays:

• Biophysical Binding Assays:
  • Fluorescence Polarization (FP): Used to measure the binding affinity ($K_D$) of various inhibitors (nutlin-3a, navtemadlin, sulanemadlin) against both human (hMDM2) and zebrafish (zMdm2) MDM2 proteins.
  • Controls: Included a modified control peptide (D-Phe substitution) and the inactive enantiomer nutlin-3b.
• Computational Modeling:
  • Molecular Dynamics (MD) Simulations: Simulated complexes of MDM2/MDM4 with small molecules and the stapled peptide.
  • Binding Energy Decomposition: Used MM/GBSA methods to analyze residue-wise contributions to binding energy, specifically investigating the impact of amino acid substitutions in the binding pocket.
• In Vivo Zebrafish Assays:
  • Transcriptional Analysis: Treated wild-type (AB) and p53-mutant (tp53zdf1/zdf1) embryos with compounds. Measured mRNA levels of key targets (cdkn1a, mdm2, Δ113p53, baxa, puma) via RT-qPCR.
  • RNA Sequencing (RNA-seq): Performed bulk RNA-seq on treated embryos followed by Gene Set Enrichment Analysis (GSEA) of KEGG pathways.
  • Apoptosis Detection: Used Acridine Orange staining on embryos at 30 hours post-fertilization (hpf) to quantify apoptotic cells.
  • Positive/Negative Controls: Roscovitine (p53 activator), Camptothecin (apoptosis inducer), and radiation (20 Gy) were used for validation.

3. Key Contributions

• Identification of a Species-Specific Barrier: The study definitively identified that a single amino acid substitution (Histidine to Proline at position 96/95) in the zebrafish Mdm2 binding pocket is responsible for the drastically reduced affinity of small-molecule inhibitors.
• Validation of a Novel Tool: The authors demonstrated that the stapled peptide sulanemadlin overcomes this barrier, retaining high binding affinity for zebrafish Mdm2 and effectively activating p53 in vivo.
• Decoupling Activation from Apoptosis: The study established that sulanemadlin can induce p53-mediated cell cycle arrest without triggering the massive apoptosis typically seen with DNA damage or roscovitine treatment.

4. Key Results

A. Biophysical and Computational Findings

• Small Molecules: Nutlin-3a and Navtemadlin showed significantly reduced affinity for zMdm2 compared to hMDM2 (e.g., Navtemadlin affinity dropped ~300-fold).
  • Mechanism: MD simulations revealed that in hMDM2, residue H96 forms a stabilizing hydrogen bond with the inhibitors. In zMdm2, this is a Proline (P95), which cannot form this bond, leading to a loss of binding energy.
• Stapled Peptide (Sulanemadlin): Retained sub-nanomolar/nanomolar affinity for both hMDM2 and zMdm2.
  • Mechanism: The stapled peptide mimics the $\alpha$-helical structure of the p53 transactivation domain, engaging a broader interface and preserving key interactions (F19, W23, L26) that are less dependent on the specific H96 residue.

B. Transcriptional Activation

• Gene Expression: In wild-type zebrafish embryos, sulanemadlin (≥1 μM) significantly upregulated:
  • mdm2 (negative feedback loop).
  • Δ113p53 (a zebrafish-specific isoform).
  • cdkn1a (cell cycle arrest marker, ~10-fold increase).
• Specificity: No significant upregulation was observed in p53-mutant embryos, confirming the effect is p53-dependent.
• Selectivity: Unlike radiation or roscovitine, sulanemadlin did not significantly upregulate pro-apoptotic genes (baxa, puma) at the tested concentrations.

C. Phenotypic Outcomes

• Apoptosis Assay: Acridine Orange staining showed no detectable increase in apoptotic cells in sulanemadlin-treated embryos, whereas positive controls (Camptothecin, Radiation) induced massive apoptosis.
• RNA-seq Pathway Analysis: Confirmed upregulation of the p53 signaling pathway and downregulation of DNA replication pathways. Roscovitine treatment, in contrast, induced broad metabolic and ribosomal changes, highlighting the specificity of sulanemadlin.

5. Significance

This paper provides a critical breakthrough for zebrafish research:

1. New Pharmacological Tool: Sulanemadlin is the first compound shown to specifically activate p53 in zebrafish without inducing confounding apoptosis or off-target stress responses.
2. Mechanistic Insight: It elucidates the structural basis for the species-specific failure of small-molecule MDM2 inhibitors, explaining why previous attempts to use them in zebrafish failed.
3. Disease Modeling: By enabling the selective activation of cell cycle arrest without killing the organism, this tool allows researchers to study p53's role in aging, diabetes, and cancer development in a living vertebrate system with high physiological relevance.
4. Therapeutic Implications: It suggests that stapled peptides may be superior to small molecules for targeting p53-MDM2 interactions in species with specific binding pocket variations, potentially guiding future drug design for non-mammalian models or specific human polymorphisms.